Navigation Links
Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Date:7/23/2009

nnounced in due course.

The Company has sufficient cash at hand to fund operations into August, however the Company will need to raise additional capital to fund its clinical trials and other operating activities, and repay indebtedness in due course. Shareholders should be aware that if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is in a large Phase II clinical trial in GBM, with 13 clinical sites across the U.S. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future securities registrations or other filings with the U.S. Securities and Exchange Commission ("SEC"), future treatment of patients with GBM using DCVax(R)-Brain, and other future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such a
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
2. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
3. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Oncothyreon to present at Invest Northwest 2009
6. Sirius Genomics to Present at Invest Northwest Conference
7. Northwest Biotherapeutics Secures $700,000 Equity Financing
8. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
9. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
10. Northwest Secures US$1.65 Million Debt Financing
11. Northwest Secures US$1.0 Million Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Calif. , Aug. 4, 2015 Trigemina, ... development of non-narcotic, nasally delivered, analgesic drug products, announced ... M.D., to the position of chief medical officer. Dr. ... to Trigemina, much of which has been focused in ... thrilled to add Dr. Kori to our clinical team ...
(Date:8/4/2015)... CAMBRIDGE, Mass. , Aug. 4, 2015  Blueprint ... and developing highly selective kinase drugs for genomically defined ... executive officer, will present a company overview at the ... 2015 at 1:20 p.m. EDT. A live ... the Investors section of the Blueprint Medicines website at ...
(Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015   ... announced the recent acquisition of LifeLine Cryogenics, an east ... the New York tristate area. ... tissues, and all prepaid contracts will be honored. ... of cryogenics services, offering storage of sperm, eggs, embryos, ...
(Date:8/3/2015)... 2015  ArroGen Group, an integrated advanced forensic ... Identification™ (FMID) technology Aug. 2-8 at the International ... Sacramento, Calif. FMID, a ... enforcement agents, district attorneys and government agencies to ... By analyzing chemical residues on fingerprints taken ...
Breaking Biology Technology:Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3FamilyCord Announces Acquisition of LifeLine Cryogenics 2ArroGen Previews New Fingerprint Molecular Identification Technology 2
... 13, 2008 at 5:00 am (Pacific) ... am (Eastern) / 8:00 pm (Beijing/Hong Kong), SHENYANG, ... ), a leading China-based biotechnology company focused on,researching, developing, ... release unaudited financial results,for the second quarter ended June ...
... July 29 - Federal, state, and,local forensic crime ... investigations during 2005, according to a report by ... cases included,requests for a variety of forensic services, ... examination., An estimated 359,000 cases were backlogged ...
... Discusses Impact of Bt Maize on His Farm and Family ... ... July 29, 2008 -- In a new online video released ... his family,s experience farming genetically modified Bt maize. Since ...
Cached Biology Technology:3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008 2Crime Labs Received an Estimated 2.7 Million Cases in 2005 2Crime Labs Received an Estimated 2.7 Million Cases in 2005 3South African Farmers Increase Plantings of Genetically Modified Crops 2South African Farmers Increase Plantings of Genetically Modified Crops 3
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/21/2015)... 2015 Today, ZTE announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1025 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... manufacturer in China and we are proud ... 5 for Axon , its first ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... "split magnet" system with the potential to revolutionize scientific research ... the National High Magnetic Field Laboratory at Florida State University. ... besting the 17.5 tesla French record set in 1991 for ... and engineer Nikola Tesla, is a measurement of the strength ...
... Human neural stem cells are capable of helping people ... treatment for brain tumors, a UC Irvine study suggests. ... two days after cranial irradiation restored cognitive function, as ... rats not treated with stem cells showed no cognitive ...
... fast, with harmful effects on native species, and are ... native species, such as sea urchins ( Paracentrotus lividus ... its early stages, or when seaweed densities are very ... to look at the ability of sea urchins ( ...
Cached Biology News:25 Tesla, world-record 'split magnet' makes its debut 225 Tesla, world-record 'split magnet' makes its debut 3Stem cells restore cognitive abilities impaired by brain cancer treatment 2Sea urchins cannot control invasive seaweeds 2
... reagents for the isolation of genomic DNA. ... the isolation of genomic DNA from blood. ... the isolation of genomic DNA from plants. ... be used for restriction endonuclease digestion Southern ...
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Apoptosis Detection Systems and Reagents...
...
Biology Products: